One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Factor XI Inhibition for Atrial Fibrillation: Where Do We Stand?.
doi : 10.1161/CIRCULATIONAHA.125.074100
Volume 151(20) pgs. 1433-1493,e1002-e1026 May 20, 2025
Olmesartan Restores LMNA Function in Haploinsufficient Cardiomyocytes.
Leveraging Transcriptional Readouts as a Platform for Drug Repurposing in Cardiomyopathy.
Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction.
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
Partial Heart Transplantation: Early Experience With Pediatric Heart Valve Replacements That Grow.
Diagnostic Yield and Outcomes of Incidental Thoracic Aortic Dilatation in the National Health Service Targeted Lung Health Check Program: Novel Insights from a Regional Tertiary Center in the United Kingdom.
Letter by Berry and McCartney Regarding Article, "Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention (The PITRI Trial)".
Response by Bulluck and Hausenloy to Letter Regarding Article, "Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (the PITRI Trial)".
Risk-Based Primary Prevention of Heart Failure: A Scientific Statement From the American Heart Association.
